On June 27, 2016, the United States Supreme Court denied a Petition for Writ of Certiorari filed by Sequenom, Inc. requesting the Supreme Court to clarify the scope of its Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012) decision, as applied to Sequenom’s claimed inventions. The Mayo decision, which held that a method correlating a drug dosage regimen and levels of the drug in the blood was an unpatentable law of nature, has had the profound effect of narrowing the scope of patent-eligible subject matter in the United States and has cast doubt on the validity and enforceability of previously-issued United States patents. Click here to read the full article.
top of page
Search
Recent Posts
See AllNeed any tips on protecting your company's data? Please watch the below webinar hosted by Lucas Beal. Should you have any questions or...
30
With the expansion of cryptocurrency and the opportunities to capitalize on its growth, there has been a recent flurry of sponsors...
20
The New York State Commissioner of Health (“Commissioner”) has extended the designation of COVID-19 as a “highly contagious communicable...
20
bottom of page
Comments